Rifampicin Capsules — Competitive Intelligence Brief

Rifampicin Capsules (Rifampicin Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rifamycin antibiotic. Area: Infectious Disease.

marketed Rifamycin antibiotic Bacterial RNA polymerase Infectious Disease Small molecule

Target snapshot

Rifampicin Capsules (Rifampicin Capsules) — Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rifampicin Capsules TARGET	Rifampicin Capsules	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
Vancomycin plus Gentamicin plus Rifampin	Vancomycin plus Gentamicin plus Rifampin	Michael E. DeBakey VA Medical Center	marketed	Antibiotic combination	Bacterial cell wall (vancomycin), 30S ribosome (gentamicin), bacterial RNA polymerase (rifampin)
amoxicillin rifabutin	amoxicillin rifabutin	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic (beta-lactam + rifamycin)	Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)
Rifaximin (drug)	Rifaximin (drug)	Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji	marketed	Rifamycin antibiotic	Bacterial RNA polymerase
PB 6 doses - Rifampicin and Dapsone	PB 6 doses - Rifampicin and Dapsone	University of Brasilia	marketed	Antileprosy combination therapy	Bacterial RNA polymerase (rifampicin); dihydropteroate synthase (dapsone)
Rifampicin (RIF)	Rifampicin (RIF)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Rifamycin antibiotic	Bacterial RNA polymerase (RNAP)
HR	HR	Global Alliance for TB Drug Development	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rifamycin antibiotic class)

1. Institute of Tropical Medicine, Belgium · 2 drugs in this class
2. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Bausch Health Americas, Inc. · 2 drugs in this class
5. South China Children's Leukemia Group · 1 drug in this class
6. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 drug in this class
7. TenNor Therapeutics (Suzhou) Limited · 1 drug in this class
8. The University of Texas Health Science Center at Tyler · 1 drug in this class
9. University College, London · 1 drug in this class
10. University of California, San Francisco · 1 drug in this class